CHANGES IN CARBOHYDRATE METABOLISM IN PATIENTS WITH ALCOHOLIC CIRRHOSIS OF THE LIVER ASSOCIATED WITH NON-ALCOHOLIC FATTY LIVER DISEASE DEPENDING ON THE STAGE OF DECOMPENSATION

Nataliia Matkovska; Nataliia Virstiuk; Uliana Balan

doi:10.31435/rsglobal_wos/30062019/6551

Nataliia Matkovska Assosiate Professor, Department of Therapy and Family Practice of postgraduate study faculty, Ukraine, Ivano-Frankivsk, Ivano-Frankivsk National Medical University
Nataliia Virstiuk Professor, Head of Department of of Internal Medicine of Stomatological Faculty, Ukraine, Ivano-Frankivsk, Ivano-Frankivsk National Medical University
Uliana Balan Assosiate Professor, Department of Internal Medicine No. 1, Immunopathology and Allergology named after academician Neiko Ye. M., Ukraine, Ivano-Frankivsk, Ivano-Frankivsk National Medical University

DOI: https://doi.org/10.31435/rsglobal_wos/30062019/6551

Keywords: alcoholic liver disease, non- alcoholic fatty liver disease, carbohydrate metabolism

Abstract

The purpose of the research was to study the changes in adipocytokines in patients with alcoholic liver cirrhosis (ALC) associated with non- alcoholic fatty liver disease (NAFLD) depending on the stage of decompensation. A significant increase in immunoreactive insulin, the HOMA-IR index and a decrease in the QUICKI index in patients II gr. in comparison with patients I gr. has been detected, that indicating insulin resistance (p<0.05). On the basis of the results of the analysis of the correlation between the levels of leptin, adiponectin, resistin and carbohydrate metabolism, it was found that a stronger correlation was observed in patients suffering from ALC associated with NAFLD.

References

Kalafateli M, Triantos C, Tsochatzis E, Michalaki M, Koutroumpakis E, Thomopoulos K et al. Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis. World J Gastroenterol. 2015; 21(10): 3020–3029. doi: 10.3748/wjg.v21.i10.3020.

Antwi SO, Mousa O Y, Patel T. Racial, Ethnic, and Age Disparities in Incidence and Survival of Intrahepatic Cholangiocarcinoma in the United States; 1995-2014. Annals of Hepatology. 2018; 17(2): 274-285. doi: 10.5604/01.3001.0010.8659.

Bassani L, Fernandes SA, Raimundo FV, Harter DL, Gonzalez MC, Marroni CA. Lipid profile of cirrhotic patients and its association with prognostic scores: a cross-sectional study. Arq Gastroenterol. 2015; 52 (3): doi: 10.1590/S0004-28032015000300011.

Paducheva SV, Bulatova IA, Schekotova AP, Tretyakova YI, Schekotova IV. Possibilities of using MELD scale for determining hepatic cirrhosis degree of severity. Perm Medical Journal. 2017; 34(6): 40-44. doi: 10.17816/pmj34640%44.

Boemeke L, Bassani L, Marroni CA, Gottschall CB. Lipid profile in cirrhotic patients and its relation to clinical outcome. Arq Bras Cir Dig. 2015;28(2):132-135. doi: 10.1590/S0102-67202015000200012.

Privitera G, Spadaro L, Marchisello S, Fede G, Purrello F. Abnormalities of Lipoprotein Levels in Liver Cirrhosis: Clinical Relevance. LLC, part of Springer Nature 2017; https://doi.org/10.1007/s10620-017-4862-x.

Gorgui J, Gasbarrino K, Georgakis MK, Karalexi MA, Nauchec B, Petridou ET et al. Circulating adiponectin levels in relation to carotid atherosclerotic plaque presence, ischemic stroke risk, andmortality:Asystematic review andmeta-analyses. Metabolism. 2017; 69: 51-66. doi: 10.1016/j.metabol.2017.01.002.

Baltieri L, Chaim EA, Chaim FDM, Utrini MP, Gestic MA, Cazzo E. Correlation between nonalcoholic fatty liver disease features and levels of adipokines and inflammatory cytokines among morbidly obese individuals. Arq Gastroenterol. 2018; 55 (3): 247-251. doi: 10.1590/S0004-2803.201800000-62.

Polyzos SA, Kountourasa J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism. 2016; 65 (8): 1062-1079. doi: 10.1016/j.metabol.2015.11.006.

Jamali R, Hatami N, Kosari F. The Correlation Between Serum Adipokines and Liver Cell Damage in Non-Alcoholic Fatty Liver Disease. Hepat Mon. 2016 May; 16(5):e37412. doi: 10.5812/hepatmon.37412.

Abenavoli L, Milic N, Di Renzo L, Preveden T, Medić-Stojanoska M, De Lorenzo A. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2016; 22: 7006-7016. doi: 10.3748/wjg.v22.i31.7006.

Buechler C, Haberl E, Rein-Fischboeck L, Aslanidis C. Adipokines in Liver Cirrhosis. International Journal of Mollecular Sciences. 2017;18 (7). 1392. doi: 10.3390/ijms18071392.

Boutari C, Perakakis N, Mantzoros CS. Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease. Endocrinol Metab. 2018;33(1):33-43. doi: 10.3803/EnM.2018.33.1.33.

Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions. Int J Mol Sci. 2017; 18: 1649. doi: 10.3390/ijms18081649.

Murad A, Hassan H, Husein H, Ayad A. Serum resistin levels in nonalcoholic fatty liver disease and their relationship to severity of liver disease. Journal of Endocrinology, Metabolism and Diabetes of South Africa. 2010; 15(1): 53-56. doi: 10.1080/22201009.2010.10872225.

Ajmera V, Perito ER, Bass NM, Terrault NA, Yates KP, Gill R et al. Novel Plasma Biomarkers Associated with Liver Disease Severity in Adults with Nonalcoholic Fatty Liver Disease. Hepatology. 2017; 65(1): 65–77. doi:10.1002/hep.28776.

Jamali R, Razavizade M, Arj A, Aarabi MH. Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease. World J Gastroenterol. 2016;22(21): 5096-5103. doi: 10.3748/wjg.v22.i21.5096.

Panera N, Della Corte C, Crudele A, Stronati L, Nobili V, Alisi A. Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines. Expert review of gastroenterology & hepatology. 2015; 10 (3): 393-403. doi: 10.1586/17474124.2016.1110485.

Gierej P, Gierej B, Kalinowski P, Wróblewski T, Paluszkiewicz R, Kobryń K et al. Expression of resistin in the liver of patients with non-alcoholic fatty liver disease. Pol J Pathol. 2017; 68 (3): 225-233. doi: 10.5114/pjp.2017.67583.